-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Partnering With Your Hospital On 340B

Program: Special-Interest Sessions
Session: Special Session on Sickle Cell Disease Centers
Saturday, December 9, 2023, 9:30 AM-11:00 AM

Julie Kanter, MD

Division of Hematology and Oncology, University of Alabama At Birmingham, Birmingham, AL

Disclosures: Kanter: Chiesi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Austin Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bausch: Honoraria; Watkins, Lourie, Roll&Chance: Consultancy; Guidepoint Global: Consultancy; Fulcrum: Consultancy; ECOR1: Consultancy; Beam: Consultancy, Honoraria; OptumRx: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Bluebird Bio: Consultancy; GLG: Consultancy; Cowen: Consultancy.

See more of: Special Session on Sickle Cell Disease Centers
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>